Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial

Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, et al. Ann Intern Med. 2015;163(11):809-817.

Publication Type:

Journal Article

Authors:

Pianko, Stephen; Flamm, Steven L.; Shiffman, Mitchell L.; et, al

Source:

Ann Intern Med, Volume 163, Issue 11, p.809-817 (2015)

Keywords:

Adult, Aged, Antiviral Agents, Carbamates, Drug Administration Schedule, Drug Therapy, Combination, Female, Genotype, Hepacivirus, Hepatitis C, Chronic, Heterocyclic Compounds, 4 or More Rings, Humans, Liver Cirrhosis, Male, Middle Aged, Ribavirin, RNA, Viral, sofosbuvir, Treatment Outcome, Young Adult

Cited On:

External Third-party Web Link:

https://www.ncbi.nlm.nih.gov/pubmed/26551263

Export Citation:

RIS Format

Top